AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

DACLATASVIR

9 registrations across 3 African markets— 3 active

Markets with DACLATASVIR

Recent registrations

Brand / ProductMarketHolderStatusExpires
MYDEKLA_60 60MG FILM TABLET
FILM TABLET
🇲🇼MalawiexpiredMar 2025
DACLAR 60MG COMPRIME BOITE DE 28🇨🇮Côte d'IvoireLABORATOIRE PHARMACEUTIQUE GALENICAexpiredJan 2023
VIDAC 30MG COMPRIME PELLICULE BOITE DE 28🇨🇮Côte d'IvoireHETERO LABS LIMITEDexpiredJan 2023
VIDAC 60MG COMPRIME PELLICULE BOITE DE 28🇨🇮Côte d'IvoireHETERO LABS LIMITEDexpiredJan 2023
DAKTAVIRA 60MG COMPRIME BOITE DE 30🇨🇮Côte d'IvoireLABORATOIRE EUROPEAN EGYPTIAN PHARMACEUTexpiredJan 2021
MYDEKLA_30 30MG FILM COATED
FILM COATED
🇲🇼MalawiexpiredJun 2020
VIRDAC
comprimé / 30 mg
🇸🇳SenegalHETERO LABS LIMITED (UNIT-VI) TSIIC FORMULATION SEZactive
VIRDAC
comprimé / 60 mg
🇸🇳SenegalHETERO LABS LIMITED (UNIT-VI) TSIIC FORMULATION SEZactive
MYDEKLA
comprimé pelliculé / 60 mg
🇸🇳SenegalMYLAN LABORATORIES LTDactive

DACLATASVIR in Africa — Regulatory Overview

DACLATASVIR is registered across 3 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Côte d'Ivoire, Senegal, Malawi. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 3 (33%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.